Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Net Income for 6 consecutive years, with -$56.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 29.68% to -$56.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$209.1 million, a 45.83% decrease, with the full-year FY2024 number at -$160.8 million, down 59.74% from a year prior.
  • Net Income was -$56.9 million for Q3 2025 at 4D Molecular Therapeutics, down from -$54.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$7.6 million in Q2 2021 to a low of -$56.9 million in Q3 2025.
  • A 5-year average of -$31.6 million and a median of -$28.7 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: soared 60.71% in 2023, then crashed 334.17% in 2024.
  • 4D Molecular Therapeutics' Net Income stood at -$25.1 million in 2021, then decreased by 9.2% to -$27.4 million in 2022, then fell by 17.85% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then dropped by 14.51% to -$56.9 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Net Income are -$56.9 million (Q3 2025), -$54.6 million (Q2 2025), and -$48.0 million (Q1 2025).